Sarepta Therapeutics To Join S&P Midcap 400, Effective June 3
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics (SRPT) will join the S&P MidCap 400, replacing Shockwave Medical (SWAV) effective June 3. Johnson & Johnson (JNJ) is acquiring Shockwave Medical, with the deal expected to close soon.
May 29, 2024 | 9:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson is acquiring Shockwave Medical, which will result in Shockwave being replaced by Sarepta Therapeutics in the S&P MidCap 400.
The acquisition of Shockwave Medical by Johnson & Johnson is a strategic move that could enhance JNJ's portfolio, potentially leading to a positive short-term impact on JNJ's stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Sarepta Therapeutics will join the S&P MidCap 400, which could increase its visibility and attract more institutional investors.
Joining the S&P MidCap 400 can lead to increased visibility and potentially more investment from institutional investors, which could positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Shockwave Medical will be replaced by Sarepta Therapeutics in the S&P MidCap 400 due to its acquisition by Johnson & Johnson.
Shockwave Medical's removal from the S&P MidCap 400 is a result of its acquisition by Johnson & Johnson. The stock price impact is neutral as the acquisition is already priced in.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100